- RESEARCH HIGHLIGHT
- 30 April 2026
A biomarker shows which people with certain types of breast cancer are more likely to respond to an immune-based therapy.
Trending
- ‘I’ve been butchered’: Women on trauma after unnecessary mastectomies
- Sudan’s civil war creates dangerous journeys to get cancer care
- Armouring GPC3 CAR T cells for hepatocellular carcinoma: how much is enough and what comes next?
- TWF1 inhibition overcomes cisplatin resistance in NSCLC by inducing ferroptosis via p53-dependent SLC7A11 repression and autophagy-mediated glutathione metabolism reprogramming
- PGC1α-mediated upregulation of PHD2 represses HIF-signaling, limiting prostate cancer progression
- New NHS cancer drug Enhertu is ‘bittersweet’ for Crawley widower
- ESR1-Directed Treatment Options in HR+/HER2− mBC
- Differentiating Mutagenesis From Genotoxic Risk in Secondary Malignancies
Friday, September 18
